drugset / Trial / NCT04708340
Tolerability and Efficacy of RJX in Patients With COVID-19
RandomizedParallel-groupDouble-blindTreatment
Summary
This study is designed as a 2-part, 2-cohort, double-blind, randomized, placebo controlled, multicenter Phase 1/2 study to evaluate the safety, tolerability and efficacy of RJX in patients with COVID-19.
Timeline
- Start
- 2021-03-25
- Primary completion
- 2022-10
- Completion
- 2023-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Epsom salt | Unknown | — | Intravenous |
| Comparator | Nicotinamide | Other / unclassified | — | Intravenous |
| Comparator | Pyridoxine | Unknown | — | Intravenous |
| Comparator | Riboflavin-5-phosphate | Other / unclassified | — | Intravenous |
| Comparator | Thiamine | Other / unclassified | — | Intravenous |
| Comparator | Vitamin B12 | Other / unclassified | — | Intravenous |
| Comparator | Vitamin C | Other / unclassified | — | Intravenous |
| Comparator | calcium d-pantothenate | Unknown | — | Intravenous |
| Comparator | sodium bicarbonate | Diagnostic / imaging agent | — | Intravenous |